Skip Navigation LinksNR21-123

office of communications

Contact :

Office of Communications

CDPHpress@cdph.ca.gov

CDPH Issues Statement on Johnson & Johnson/Janssen COVID-19 Vaccine

Date: April 13, 2021
Number: NR21-123
Contact: CDPHpress@cdph.ca.gov


SACRAMENTO – Today the California Department of Public Health (CDPH) issued a statement from Dr. Erica Pan, state epidemiologist, regarding the Johnson & Johnson/Janssen COVID-19 vaccine.

"Today, the CDC and FDA have recommended a temporary pause in the use of the Johnson & Johnson COVID-19 vaccine out of an abundance of caution. Of over 6.8 million doses administered nationally, there have been six reported cases of a rare and severe type of blood clot with symptoms occurring 6 to 13 days after vaccination.

"California is following the FDA and CDC's recommendation and has directed health care providers to pause the use of the Johnson & Johnson vaccine until we receive further direction from health and safety experts. Additionally, the state will convene the Western States Scientific Safety Review Workgroup to review the information provided by the federal government on this issue. As the federal government has said, we do not expect a significant impact to our vaccination allocations. In California, less than 4% of our vaccine allocation this week is the Johnson & Johnson vaccine." 

For more information about the adverse effects, and what to do if you are experiencing symptoms, please contact your healthcare provider. We will provide additional details on what this means for our state efforts as they become available.

The joint CDC and FDA statement can be found here.

Page Last Updated :